Files
Download Full Text (153 KB)
Contents
- Advances in Prostate Cancer Treatment
- Everyday Drugs Show New Promise for Cancer
- Are COX-2 Inhibitors Safe?
- House Call: Myths & Facts about Cancer Prevention
- DiaLog: Neoadjuvant Trials in Prostate Cancer, by Paul Mathew, MD, Assistant Professor, Department of Genitourinary Medical Oncology
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Publication Date
2004
Publisher
The University of Texas MD Anderson Cancer Center
City
Houston, Texas
Keywords
Keyomarsi, Khandan; Kuban, Deborah A.; Pettaway, Curtis A.; Mathew, Paul; Whitmore, Willet, 1917-; Stage, Christopher; Lu, Karen; Lynch, Patrick; Arun, Banu; Levin, Bernard, 1942-; Efuet, Ekem; Prostatic Neoplasms; Prostate-Specific Antigen; Neoplasm Grading; Prostatectomy; Watchful Waiting; Radiotherapy; Brachytherapy; Cryosurgery; Neoplasms; Chemoprevention; Aspirin; Docetaxel; Imatinib Mesylate; Chemotherapy, Adjuvant; Neoadjuvant Therapy; Neoplasm Metastasis; Rosiglitazone; Hydroxymethylglutaryl CoA Reductases; Rosiglitazone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors.
Disciplines
History of Science, Technology, and Medicine | Oncology
Recommended Citation
Galloway, David; Matias, Katie Prout; Witter, Diane; and Mathew, Paul MD, "OncoLog, Volume 49, Number 12, December 2004" (2004). OncoLog MD Anderson's Report to Physicians (All issues). 135.
https://openworks.mdanderson.org/oncolog/135
Conditions Governing Access
Open
